Phase I/II study of VEGFR1/2-derived peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for metastatic colorectal cancer with KRAS genetic mutation as a third-line therapy
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
Interventions: KRAS genetic sequence, peptide vaccination, TS1 Primary outcome(s): First step (clinical phase I) Primary Endpoint: RD Second step (clinical phase II) Primary Endpoint: DCR Study Design: Single arm Non-randomized
创建时间：
2009-12-15
